Hypogonadismus obézních mužů
Authors:
Luboslav Stárka; Michaela Dušková; Martin Hill
Authors‘ workplace:
Endokrinologický ústav Praha
Published in:
Vnitř Lék 2020; 66(8): 24-27
Category:
Overview
Male hypogonadism associated with obesity by yet not fully understood mechanisms promote fat depositions and on contrary obesity induces decrease of androgen production. It is necessary to diagnose hypogonadism correctly and to treat it. The definition of hypogonadism is based on subnormal levels of circulating testosterone and on the occurrence of symptoms, which, however, are not much specific. As obesity decreases substantially the concentrations of sex hormone binding globulin SHBG it is recommended in these men to check not only the level of total testosterone but also the concentration of free testosterone or the value of the index of free androgens. Proven hypogonadism in obese men should be treated as well as by testosterone substitution as the body mass reduction. The most effective treatment in this respect is considered bariatric surgery.
Keywords:
male hypogonadism – obesity – SHBG – testosterone.
Sources
1. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2018; 103: 1715–1744.
2. Čáp J. Androgenní deficit a diabetes. Vnitř Lék 2012; 58: 228–231.
3. Dhindsa S, Ghanim H, Batra M, et al. Hypogonadotropic hypogonadism in men with diabesity. Diabetes Care 2018; 41: 1516–1525.
4. Dohle GR, Arvec S, Bettocchi C, Jones TH, et al. Male hypogonadism. Guidelines EAU 2017. http//uroweb.org/guideline/m ale‑hypogonadism/.
5. Escobar‑Morreale HF, Santacruz E, Luque‑Ramírez M, et al. Prevalence of ‘obesity‑associated gonadal dysfunction’ in severely obese men and women and its resoluti‑ on after bariatric surgery: a systematic review and meta‑analysis. Hum Reprod Upda‑ te 2017; 23: 390–408.
6. Fryšák Z, Karásek D, Halenka M. Hypogonadismus mužů – příčiny, diagnostika, léčba. Urol pro praxi 2010; 11: 75–77.
7. Fui MNT, Dupuis P, Grossmann M. Lowered testosterone in male obesity: mechanism, morbidity and management. Asiian Jj Adrology 2014; 16: 223–231.
8. Grossmann M. Hypogonadism and male obesity. Focus on unresolved questions. Clin Endocrinol (Oxf) 2018; 89: 11–21.
9. Hána V, Kosák M, Hána jr. V. Hypogonadismus u mužů a jeho léčba. Čas Lék Čes 2017; 156: 258–265.
10. Hanuš M., Matoušková M, Hill M, et al. Hormonal homeostasis in a group of 216 ageing Czech males and correlation with responses to a questionnaire of the University of St. Louis. Aging Male 2006; 9: 103–110.
11. Kahn BE, Brannigan RE. Obesity and male infertility. Curr Opin Urol 2017; 27: 441–445.
12. Kubíček V. Racionální substituční terapie androgeny pro muže. Andrologie 2000, 1: 1–9.
13. Molina‑Vega M, Muñoz‑Garach A, Damas‑Fuentes M, et al. Secondary male hypogonadism: a prevalent but overlooked comorbidity of obesity. Asian J Androl 2018; 20: 531–538.
14. Mushannen T, Cortez P, Stanford FC, et al. Obesity and hypogonadism – A narrative review highlighting the need for high‑quality data in adolescents. Children (Basel) 2019; 6: E63.
15. Noe S. Adipositas‑assoziirter Hypogonadism. Endocrinol Info 2019; Sonderheft: 24–27.
16. Pivonello R, Menafra D, Riccio E, et al. Metabolic disorders and male hypogonadotropic Hypogonadism. Front. Endocrinol 2019; https://doi.org/10.3389/fendo.2019.00345.
17. Poršová‑Dutoit I. Mužský hypogonadism. Nedostatečná funkce mužských pohlavních žláz. Praha: Maxdorf 2005, 183 s.
18. Pospisilova H, Duskova M, Hill M, et al. Changes of steroidogenesis subject to weight growth. ECE 2013 Copenhagen, http://www.endocrine‑abstracts.org/ea/0032/ea0032p976.htm
19. Ring J, Welliver C, Parenteau M, et al. The utility of sex hormone‑binding globulin in hypogonadism and infertile males. J Urol 2017; 197: 1326–1331.
20. Stárka L, Jirásek JE. Hypogonadismus mužský. In: Stárka L Endokrinologie. Lékařské repetitorium. Praha: Triton 2010, 98–124.
21. Stárka L. Hormonální substituční terapie u stárnoucích mužů. Urologie pro praxi | 2009; 10(5)
22. Stárka L. Substituční léčba testosteronem u mužů v andropauze. Prakt Lék 2007; 87: 184–188.
23. Stárka L. Mužský hypogonadismus a civilizační onemocnění. Čas Lék Čes 2012; 151: 69–72.
24. Šrámková T. Bez testosteronu to nepůjde. In: Kvapil M. Diabetologie 2018. Praha: Triton 2018; 321–333.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2020 Issue 8
Most read in this issue
- Dialysis patient in internal medicine inpatient ward
- Obesity-associated changes in drug pharmacokinetics
- Heparin induced thrombocytopenia and up to date options of treatment – review of literature
- Danger of the sea‑complications After Scorpion Fish Attack